Press Release: “Compass Pathways today announced statistically significant positive results in two pivotal Phase 3 trials evaluating COMP360”

Press Release Compass Pathways today announced statistically significant positive results in two pivotal Phase 3 trials evaluating COMP360 – a synthetic, proprietary formulation of psilocybin – in treatment-resistant depression (TRD). Notably, COMP360 is the first classic psychedelic to consistently achieve a highly-significant result and clinically meaningful effect, with a well-tolerated safety profile in this historically difficult to treat patient population. Details can […]